Hints and tips:
Related Special Reports
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...One such flashpoint recently involved AbbVie, which, along with Eli Lilly, exited an NHS pricing agreement in the UK over a rise in clawback payments....
...The recent shift in tone has seen Warren Buffett’s Berkshire Hathaway and drugmaker Eli Lilly overtake Tesla in terms of market capitalisation....
...Novo Nordisk and Eli Lilly have struggled to keep up with soaring demand for obesity treatments....
...Vertex “is probably going to be one of the fastest-growing top lines outside of the weight-loss drugmakers [Eli] Lilly and Novo [Nordisk],” predicts Debjit Chattopadhyay, a healthcare analyst at Guggenheim...
...That view was echoed by Tricia Bryan, a WeightWatchers member who has lost 17lbs since pairing the Core programme with a Clinic prescription for Eli Lilly’s Zepbound. “The medication is a tool....
...Trading at around 9 times forward earnings, a fraction of peers Eli Lilly and Novo Nordisk....
...JD Vargas, a partner at EQT, said the expected opening of large plants by companies such as Tesla, Albermarle, Eli Lilly, Chevron and BASF would add to waste infrastructure demand....
...At Indianapolis-based Eli Lilly, about 80 per cent of endotoxin testing capacity has converted to rFC and regulators have approved eight products utilising these tests....
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...But after enrolling in a trial of an experimental therapy developed by Eli Lilly, the 65-year-old former teacher says her memory has improved and she is able to do things she previously found difficult....
...The scheme excludes the most innovative drugs and some sales from small- and medium-sized companies....
...The list of top performers is littered with defensive healthcare names (Eli Lilly, Amgen, Regeneron, McKesson) whereas the worst performers are a who’s who of highly levered economically sensitive stocks...
...Eli Lilly, Amgen, Pfizer and Regeneron are among the companies aiming to compete with market leader Novo Nordisk in a category which analysts say is rapidly becoming a healthcare priority and could produce...
...monoclonal antibody therapy sotrovimab from GlaxoSmithKline and Vir Biotechnology, and Eli Lilly’s bebtelovimab....
...Hopes are high for Eli Lilly’s new obesity drug Mounjaro. Like a similar drug from Novo Nordisk, it targets a brain area that regulates appetite....
...These drugs face competition from the likes of GSK, Moderna and Eli Lilly and there is no evidence Pfizer has a particular edge, he said. “It’s a similar story across the board,” he added....
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...Key economic and company reports Here is a more complete list of what to expect in terms of company reports and economic data this week....
...Shares in Eli Lilly and Roche also gained....
...Nonetheless, the drug represents a major coup for Eisai, a company dwarfed by rivals such as Roche and Eli Lilly....
...But he said it would not bury the theory altogether because of forthcoming results from late-stage trials of three drugs from Roche and Eli Lilly....
...The US drugs regulator has rescinded its authorisation for the monoclonal antibody treatments made by Eli Lilly and Regeneron, which proved highly effective at fighting earlier strains of Covid-19 but do...
...Last month a US Food and Drug Administration committee voted against recommending approval of a lung cancer treatment developed by Innovent Biologics and Eli Lilly because the trial was conducted in China...
...Aduhelm’s regulatory success has encouraged the pursuit of similar antibody treatments (a decision on Eli Lilly’s donanemab may come this year)....
International Edition